MSF Field Research > 1 Published Research and Commentary > HIV/AIDS > Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.

Please use this identifier to cite or link to this item:     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!

Download this article:
View/Open File Description Size Format
Wandeler tenofovir in second-line art in zambia and south africa collaborative analysis of cohort studies JAIDS.pdf452KbAdobe PDF

Title: Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
Authors: Wandeler, Gilles
Keiser, Olivia
Mulenga, Lloyd
Hoffmann, Christopher J
Wood, Robin
Chaweza, Thom
Brennan, Alana
Prozesky, Hans
Garone, Daniela
Giddy, Janet
Chimbetete, Cleophas
Boulle, Andrew
Egger, Matthias
Affiliation: Division of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland.
Citation: Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies. 2012, 61 (1):41-8 J. Acquir. Immune Defic. Syndr.
Journal: Journal of acquired immune deficiency syndromes (1999)
Issue Date: 1-Sep-2012
DOI: 10.1097/QAI.0b013e3182632540
PubMed ID: 22743595
Additional Links:
Abstract: Tenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART) in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing TDF in cohort studies from Zambia and the Republic of South Africa (RSA).
Type: Article
Language: en
Description: Article approval pending
Keywords: HIV/AIDS
MeSH: Adenine
Africa South of the Sahara
Anti-Retroviral Agents
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Cohort Studies
HIV Infections
Middle Aged
Phosphonic Acids
South Africa
Treatment Outcome
Viral Load
ISSN: 1944-7884
Rights: Archived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999)
Appears in topics: HIV/AIDS

Related articles on PubMed
Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
Wandeler G, Gerber F, Rohr J, Chi BH, Orrell C, Chimbetete C, Prozesky H, Boulle A, Hoffmann CJ, Gsponer T, Fox MP, Zwahlen M, Egger M, IeDEA Southern Africa
Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, Maxwell N, Maskew M, Prozesky H, Fox MP, Westfall A, Egger M, IeDEA Southern Africa Collaboration
2011 Sep 10
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Mulenga L, Musonda P, Mwango A, Vinikoor MJ, Davies MA, Mweemba A, Calmy A, Stringer JS, Keiser O, Chi BH, Wandeler G, IeDEA-Southern Africa
2014 May
Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.
Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, Bolton-Moore C, Chintu N, Mulenga PL, Stringer EM, Sheneberger R, Mwaba P, Stringer JS
2010 May 1
See all 201 articles

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.


OR Logo Powered by Open Repository | Cookies


MSF logo MSF Field Research

Sep 3, 2015